UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed

Journal of clinical oncology, 2002-01, Vol.20 (1), p.205-213

Keating, M. J.

2002

Volltextzugriff (PDF)

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

Journal of clinical oncology, 1995-01, Vol.13 (1), p.210-221

1995

Volltextzugriff (PDF)

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

Annals of oncology, 2012-01, Vol.23 (1), p.200-205

2012

Volltextzugriff (PDF)

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study

Annals of oncology, 2007-01, Vol.18 (1), p.168-172

2007

Volltextzugriff (PDF)

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer

Annals of oncology, 2007-06, Vol.18 (6), p.1064-1070

2007

Volltextzugriff (PDF)

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

European journal of cancer (1990), 1999-01, Vol.35 (1), p.54-59

1999

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

Annals of oncology, 1995-02, Vol.6 (2), p.141-151

1995

Volltextzugriff (PDF)

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

Journal of clinical oncology, 1997-03, Vol.15 (3), p.1080-1086

1997

Volltextzugriff (PDF)

Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea

JNCI : Journal of the National Cancer Institute, 1994-03, Vol.86 (6), p.446-449

1994

Volltextzugriff (PDF)

587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines

European journal of cancer (1990), 2014-11, Vol.50, p.189-189

2014

Volltextzugriff (PDF)

567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines

European journal of cancer (1990), 2014-11, Vol.50, p.183-183

2014

Volltextzugriff (PDF)

568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM)

European journal of cancer (1990), 2014-11, Vol.50, p.184-184

2014

Volltextzugriff (PDF)

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

Journal of clinical oncology, 1997-01, Vol.15 (1), p.251-260

1997

Volltextzugriff (PDF)

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Annals of oncology, 2007-01, Vol.18 (1), p.52-57

2007

Volltextzugriff (PDF)

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

Journal of clinical oncology, 2002, Vol.20 (1), p.205-213

2002

Volltextzugriff (PDF)

5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

European journal of cancer (1990), 2014-11, Vol.50, p.196-196

2014

Volltextzugriff (PDF)

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

The Lancet. Haematology, 2016-04, Vol.3 (4), p.e186-e195

2016

Volltextzugriff (PDF)

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2745-2751

1998

Volltextzugriff (PDF)

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

British journal of cancer, 2000-08, Vol.83 (4), p.431-437

2000

Volltextzugriff (PDF)

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients

Annals of oncology, 2004-07, Vol.15 (7), p.1018-1024

2004

Volltextzugriff (PDF)

CPT-11 (Irinotecan) in the treatment of colorectal cancer

European journal of cancer (1990), 1995-07, Vol.31 (7), p.1283-1287

1995

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer

Journal of clinical oncology, 1996-10, Vol.14 (10), p.2688-2695

1996

Volltextzugriff (PDF)

CPT-11-induced cholinergic effects in cancer patients

Journal of clinical oncology, 1993-01, Vol.11 (1), p.196-197

1993

Volltextzugriff (PDF)

BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

Annals of oncology, 2015-03, Vol.26, p.ii10

2015

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Aktive Filter

KollektionPsychology & Behavioral Sciences Collection

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Englisch
(62)
Französisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(50)
Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Female
(36)
Aged
(34)
Oncology
(34)
Middle Aged
(33)
Biological And Medical Sciences
(32)
Medical Sciences
(32)
Male
(29)
Adult
(28)
Pharmacology. Drug Treatments
(28)
Antineoplastic Agents
(26)
Chemotherapy
(21)
Doxorubicin - Analogs & Derivatives
(15)
Camptothecin - Analogs & Derivatives
(12)
Colorectal Neoplasms - Drug Therapy
(11)
Doxorubicin - Adverse Effects
(11)
Drug Administration Schedule
(11)
Drug Evaluation
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea

587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines

567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines

568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM)

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients

CPT-11 (Irinotecan) in the treatment of colorectal cancer

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer

CPT-11-induced cholinergic effects in cancer patients

BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

Aktive Filter

Suchergebnisse filtern